Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Compugen logo — A clinical-stage cancer immunotherapy company and a pioneer...

Compugen

A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery

Founded 1993 Israel Israel 112 employees IPO Total: $126.00M Analytics, Biotechnology +3

General Information

Company Name Compugen
Founded Year 1993
Location Israel Israel +1
Employees 112
Industries Analytics, Biotechnology, Computing +2
Funding Stage IPO
Social

Get notified when Compugen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Compugen's CEO's participation in an upcoming podcast focused on AI-Powered Cancer Drug Discovery highlights the company's sustained strategic emphasis on leveraging its computational platform for novel therapeutic identification. This public engagement reinforces its positioning at the forefront of applying AI/ML technologies to advance cancer immunotherapy and underscores the long-term value of its Unigen™ platform.

Signal Types
Event Strategic Communication
Strategic Labels
AI Integration Thought Leadership Market Positioning
Next Move: Product Development
·
Impact: 4/10
·
Ideal For: Public Market Biotech Investors — AI/ML Focus

About Compugen

Compugen is a clinical-stage company specializing in cancer immunotherapy, leveraging its AI/ML-powered computational discovery platform, Unigen™. Founded in 1993, this Israel-based firm is recognized for its pioneering role in computational target discovery.

Compugen's innovative pipeline includes proprietary programs targeting TIGIT, such as COM902, a high-affinity anti-TIGIT antibody in Phase 1, and rilvegostomig, an antibody in Phase 3 via a license with AstraZeneca. Additionally, their early-stage assets, COM701 and GS-0321 (licensed to Gilead), underline the potential to redefine cancer immunotherapy by exploring novel biological pathways.

Listed on Nasdaq and the Tel Aviv Stock Exchange under CGEN, Compugen secured its latest funding of $20.00M through a Post-Ipo Equity investment in November 2021 from Bristol-Meyers Squibb. This financial backing and strategic partnerships position Compugen as a promising contender in the biotechnology sector, targeting the immune system to combat cancer effectively.

Taxonomy: Cancer Immunotherapy, Computational Target Discovery, AI/ML Powered Discovery, Fc-reduced Antibodies, Bispecific Antibody Development, TIGIT Targeting Programs, PD-1/TIGIT Bispecific Antibodies, Immuno-Oncology, In Silico Prediction, Pharmaceutical Partnerships, Machine Learning Systems, Drug Development Pipeline, Therapeutic Discovery, In Silico Hypothesis-Driven Discovery, Experimental Validation

Services & Products

Drug Discovery
Clinical Trials
Therapeutic Development
AI/ML Application in Drug Research

Target Customers

Pharmaceutical Companies Biotech Investors Healthcare Providers Cancer Research Organizations Oncology Researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• 1
Investor
01 Nov 2021
Post Ipo Equity •••••• - 01 Mar 2020
Post Ipo Equity •••••• 1
Investor
01 Oct 2018
IPO •••••• - 01 Jul 2000
IPO •••••• - 01 Jan 2000

View All 6 Funding Rounds

Compugen Alternatives & Competitors

View All Alternatives
Compugen vs
Akeso Biopharma
Akeso Biopharma China

First in class and best in class therapeutic antibodies for patients worldwide. #9926.HK

Series D
105 employees
Biopharma, Biotechnology
Compare Compugen vs Akeso Biopharma
Compugen vs
Molecular Templates
Molecular Templates United States

Engineering the Next Generation of Therapeutics

Post Ipo Equity
26 employees
Biotechnology, Health Care
Compare Compugen vs Molecular Templates
Compugen vs
Kling Biotherapeutics
Kling Biotherapeutics The Netherlands

Amsterdam based biotech developing novel antibody based therapeutics

Unknown
16 employees
Biopharma, Biotechnology
Also compare with: Compugen vs Oxford BioTherapeutics Oxford BioTherapeutics View all alternatives

FAQ About Compugen

A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery
Compugen was founded in 1993.
Compugen is headquartered in Israel.
Compugen operates in the following industries: Analytics, Biotechnology, Computing, Health Care, Information Technology.
Compugen has approximately 112 employees.
Compugen has completed 6 funding rounds, raising a total of $126.00M. The latest funding stage is IPO.
Compugen offers: Drug Discovery, Clinical Trials, Therapeutic Development, AI/ML Application in Drug Research.
Top alternatives and competitors to Compugen include Akeso Biopharma, Molecular Templates, Kling Biotherapeutics, Oxford BioTherapeutics, Memo Therapeutics AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Compugen and Akeso Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Compugen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy